Mass spectrometry imaging for early discovery and development of cancer drugs
A drug delivery system (DDS) is a method for delivering a drug to its site of action in the body, with the goal of achieving therapeutic benefits while reducing adverse effects. Pharmacokinetics (PK) and pharmacodynamics (PD) studies have been conducted to evaluate drug delivery, but these approache...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
American Institute of Mathematical Sciences
2018-04-01
|
Series: | AIMS Medical Science |
Subjects: | |
Online Access: | http://www.aimspress.com/medicalScience/article/1934/fulltext.html |
id |
doaj-5244f51824724ef8893a87432f9d043a |
---|---|
record_format |
Article |
spelling |
doaj-5244f51824724ef8893a87432f9d043a2020-11-25T02:00:19ZengAmerican Institute of Mathematical SciencesAIMS Medical Science2375-15762018-04-015216218010.3934/medsci.2018.2.162medsci-05-02-162Mass spectrometry imaging for early discovery and development of cancer drugsMasahiro Yasunaga0Shino Manabe1Masaru Furuta2Koretsugu Ogata3Yoshikatsu Koga4Hiroki Takashima5Toshirou Nishida6Yasuhiro Matsumura7Division of Developmental Therapeutics, EPOC, National Cancer Center (6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan), JapanSynthetic Cellular Chemistry Laboratory, RIKEN (Hirosawa, Wako, Saitama 351-0198, Japan), JapanbrShimadzu Corporation (1, Nishinokyo-Kuwabaracho, Nakagyo-ku, Kyoto 604-8511, Japan), JapanbrShimadzu Corporation (1, Nishinokyo-Kuwabaracho, Nakagyo-ku, Kyoto 604-8511, Japan), JapanbrDivision of Developmental Therapeutics, EPOC, National Cancer Center (6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan), JapanDivision of Developmental Therapeutics, EPOC, National Cancer Center (6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan), JapanNational Cancer Center Hospital (5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan), JapanDivision of Developmental Therapeutics, EPOC, National Cancer Center (6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan), JapanA drug delivery system (DDS) is a method for delivering a drug to its site of action in the body, with the goal of achieving therapeutic benefits while reducing adverse effects. Pharmacokinetics (PK) and pharmacodynamics (PD) studies have been conducted to evaluate drug delivery, but these approaches are rarely used in the early stages of drug discovery and development. We demonstrated that the tumor stromal barrier inhibits drug distribution within tumor tissue, especially in refractory cancers such as pancreatic cancer. This poses an obstacle to the discovery of new drugs, and is difficult to overcome using conventional <em>in vitro</em> drug discovery methods. In addition, we are also developing new DDS drugs and antibody-drug conjugates (ADCs). These agents act via four steps: Systemic circulation, the enhanced permeability and retention (EPR) effect, penetration within the tumor tissue, and action on cells including controlled drug release. Most of these activities can be evaluated by conventional biological or pharmacological assays. However, it is difficult to examine drug distribution and controlled drug release within targeted tissues. Recent advances in mass spectrometry imaging (MSI) allow examining drug delivery much more conveniently with the off-labeling. A mass microscope, a new type of matrix-associated laser desorption/ionization (MALDI)-MSI analyzer, is a microscope coupled with an atmospheric MALDI and quadruple ion trap time-of-flight (TOF) mass spectrometer, and can provide imaging data with enhanced resolution and high sensitivity. Using a mass microscope, we succeeded in visualizing the EPR effect of a polymeric micelle drug and controlled drug release by an ADC. Currently, we are developing a new drug imaging method using electrospray ionization (ESI)-MSI. Here, we review the use of MSI in early stages of drug discovery and development, as well as our related recent work.http://www.aimspress.com/medicalScience/article/1934/fulltext.htmldrug discovery and developmentmolecular imagingmass spectrometry imaging (MSI)drug delivery system (DDS)antibody-drug conjugate (ADC)MALDI (matrix-associated laser desorption/ionization)electrospray ionization (ESI)mass microscope |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Masahiro Yasunaga Shino Manabe Masaru Furuta Koretsugu Ogata Yoshikatsu Koga Hiroki Takashima Toshirou Nishida Yasuhiro Matsumura |
spellingShingle |
Masahiro Yasunaga Shino Manabe Masaru Furuta Koretsugu Ogata Yoshikatsu Koga Hiroki Takashima Toshirou Nishida Yasuhiro Matsumura Mass spectrometry imaging for early discovery and development of cancer drugs AIMS Medical Science drug discovery and development molecular imaging mass spectrometry imaging (MSI) drug delivery system (DDS) antibody-drug conjugate (ADC) MALDI (matrix-associated laser desorption/ionization) electrospray ionization (ESI) mass microscope |
author_facet |
Masahiro Yasunaga Shino Manabe Masaru Furuta Koretsugu Ogata Yoshikatsu Koga Hiroki Takashima Toshirou Nishida Yasuhiro Matsumura |
author_sort |
Masahiro Yasunaga |
title |
Mass spectrometry imaging for early discovery and development of cancer drugs |
title_short |
Mass spectrometry imaging for early discovery and development of cancer drugs |
title_full |
Mass spectrometry imaging for early discovery and development of cancer drugs |
title_fullStr |
Mass spectrometry imaging for early discovery and development of cancer drugs |
title_full_unstemmed |
Mass spectrometry imaging for early discovery and development of cancer drugs |
title_sort |
mass spectrometry imaging for early discovery and development of cancer drugs |
publisher |
American Institute of Mathematical Sciences |
series |
AIMS Medical Science |
issn |
2375-1576 |
publishDate |
2018-04-01 |
description |
A drug delivery system (DDS) is a method for delivering a drug to its site of action in the body, with the goal of achieving therapeutic benefits while reducing adverse effects. Pharmacokinetics (PK) and pharmacodynamics (PD) studies have been conducted to evaluate drug delivery, but these approaches are rarely used in the early stages of drug discovery and development. We demonstrated that the tumor stromal barrier inhibits drug distribution within tumor tissue, especially in refractory cancers such as pancreatic cancer. This poses an obstacle to the discovery of new drugs, and is difficult to overcome using conventional <em>in vitro</em> drug discovery methods. In addition, we are also developing new DDS drugs and antibody-drug conjugates (ADCs). These agents act via four steps: Systemic circulation, the enhanced permeability and retention (EPR) effect, penetration within the tumor tissue, and action on cells including controlled drug release. Most of these activities can be evaluated by conventional biological or pharmacological assays. However, it is difficult to examine drug distribution and controlled drug release within targeted tissues. Recent advances in mass spectrometry imaging (MSI) allow examining drug delivery much more conveniently with the off-labeling. A mass microscope, a new type of matrix-associated laser desorption/ionization (MALDI)-MSI analyzer, is a microscope coupled with an atmospheric MALDI and quadruple ion trap time-of-flight (TOF) mass spectrometer, and can provide imaging data with enhanced resolution and high sensitivity. Using a mass microscope, we succeeded in visualizing the EPR effect of a polymeric micelle drug and controlled drug release by an ADC. Currently, we are developing a new drug imaging method using electrospray ionization (ESI)-MSI. Here, we review the use of MSI in early stages of drug discovery and development, as well as our related recent work. |
topic |
drug discovery and development molecular imaging mass spectrometry imaging (MSI) drug delivery system (DDS) antibody-drug conjugate (ADC) MALDI (matrix-associated laser desorption/ionization) electrospray ionization (ESI) mass microscope |
url |
http://www.aimspress.com/medicalScience/article/1934/fulltext.html |
work_keys_str_mv |
AT masahiroyasunaga massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs AT shinomanabe massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs AT masarufuruta massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs AT koretsuguogata massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs AT yoshikatsukoga massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs AT hirokitakashima massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs AT toshirounishida massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs AT yasuhiromatsumura massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs |
_version_ |
1724961392407085056 |